What’s New in the Treatment of Cocaine Addiction?
- 820 Downloads
Cocaine dependence continues to be a significant public health problem in the United States. The number of regular cocaine users has not declined significantly in the United States since 1992. Although counseling remains the treatment of choice for cocaine dependence, many cocaine-dependent patients do not respond completely to standard drug counseling. Therefore, the development of new and more effective treatments for cocaine dependence is a research priority. Progress in the understanding of the neurobiology of cocaine dependence has led to the discovery of several promising medications that have already shown encouraging results in controlled clinical trials. Other promising compounds are just becoming available for clinical trials. The use of novel psychosocial techniques such as contingency management seems to increase the efficacy of several medications used to treat cocaine dependence. New medications and new psychosocial techniques are leading to significant improvements in the treatment of cocaine dependence.
KeywordsCocaine Pharmacotherapy Relapse Withdrawal Contingency management
Dr. Kampman has served as a speaker for Reckitt-Benckiser.
Papers of particular interest, published recently, have been highlighted as: • Of importance ••Of major importance
- 1.Substance Abuse and Mental Health Services Administration: Treatment Episode Data Set (TEDS): 1994–2004. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2006.Google Scholar
- 2.Ball JK, Albright V: Drug Abuse Warning Network, 2006: national estimates of drug-related emergency department visits. In Substance Abuse and Mental Health Services Administration (SAMHSA), (OAS) OoAS. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2007:8.Google Scholar
- 8.• Hart CL, Haney M, Vosburg SK, et al.: Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008, 3:761–768. In this human laboratory trial, modafinil pretreatment reduced the subjective effects of cocaine and cocaine self-administration among cocaine-dependent individuals. CrossRefGoogle Scholar
- 10.•• Anderson AL, Reid MS, Li SH, et al.: Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009, 104:133–139. This is the most recent and largest clinical trial of modafinil for the treatment of cocaine dependence. The results of this trial suggest that modafinil, in combination with individual behavioral therapy, was effective for increasing cocaine nonuse days in participants without comorbid alcohol dependence, and was effective in reducing cocaine craving. CrossRefPubMedGoogle Scholar
- 11.Dworkin SI, Smith JE: Neurobehavioral pharmacology of cocaine. In Mechanisms of Cocaine Abuse and Toxicity. Edited by Clouet D, Ashgar K, Brown R. National Institute on Drug Abuse Research Monograph #88. Washington, DC: US Government Printing Office; 1988:185–198.Google Scholar
- 18.• Brodie JD, Case BG, Figueroa E, et al.: Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. Am J Psychiatry 2009, 166:1269–1277. This was the first double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence. In this trial, full end-of-trial abstinence was achieved in 14 vigbatrin-treated individuals (28.0%) compared with four in the placebo arm (7.5%). Twelve participants in the vigabatrin group and two in the placebo group maintained abstinence through the follow-up period. CrossRefPubMedGoogle Scholar
- 21.Cornish JL, Kalivas PW: Glutamate transmission in the nucleus accumbens mediates relapse in cocaine addiction. J Neurosci 2000, 20:1–5.Google Scholar
- 28.• Pettinati HM, Kampman KM, Lynch KG, et al.: A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav 2008, 33:651–667. In this trial, naltrexone, disulfiram, and the combination of these medications were compared with placebo for the treatment of cocaine and alcohol dependence. In the primary analyses (generalized estimating equation modeling), abstinence from cocaine as measured by cocaine-negative urines and days of self-reported abstinence from cocaine or alcohol did not differ between placebo and any of the medication groups. However, patients taking disulfiram (alone or in combination) were most likely to achieve combined abstinence from cocaine and alcohol. Secondary analyses revealed that patients taking the disulfiram–naltrexone combination were most likely to achieve 3 consecutive weeks of abstinence from cocaine and alcohol. CrossRefPubMedGoogle Scholar
- 32.•• Martell BA, Orson FM, Poling J, et al.: Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 2009, 66:1116–1123. In this trial, 115 cocaine-dependent patients were randomly assigned to receive a vaccine that stimulated the production of anticocaine antibodies or placebo. The 21 vaccinated patients (38%) who attained serum IgG anticocaine antibody levels of 43 μg/mL or higher (i.e., high IgG level) had significantly more cocaine-free urine samples than those with levels less than 43 μg/mL (i.e., low IgG level) and the placebo-receiving patients during weeks 9 to 16 (45% vs. 35% cocaine-free urine samples, respectively). The proportion of patients having a 50% reduction in cocaine use was significantly greater in those with a high IgG level than in those with a low IgG level (53% vs. 23% of patients, respectively; P = 0.048). CrossRefPubMedGoogle Scholar
- 45.• LaRowe SD, Myrick H, Hedden S, et al.: Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry 2007, 164:1115–1117. In this double-blind, placebo-controlled trial, 15 participants received NAC or placebo during a 3-day hospitalization. Participants were crossed over to receive the opposite condition on a second, identical 3-day stay occurring 4 days later. During each hospital stay, participants completed a cue reactivity procedure that involved collecting psychophysical and subjective data in response to slides depicting cocaine and cocaine use. While taking NAC, participants reported less desire to use and less interest in response to cocaine slides and watched cocaine slides for less time. NAC may be useful in reducing cocaine craving. CrossRefPubMedGoogle Scholar
- 50.• Moeller FG, Schmitz JM, Steinberg JL, et al.: Citalopram combined with behavioral treatment reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse 2007, 33:367–378. The purpose of this study was to examine whether the SSRI citalopram would reduce cocaine-positive urines in a 12-week, double-blind, placebo-controlled trial. Seventy-six cocaine-dependent patients received citalopram, 20 mg/d, or placebo along with cognitive-behavioral therapy and contingency management. Citalopram-treated patients showed a significant reduction in cocaine-positive urines during treatment compared with placebo-treated patients. CrossRefPubMedGoogle Scholar